VEN+AZA-5 clinical trials

Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy

This study looks at a new way to treat acute myeloid leukaemia (AML) in people who can't have standard, strong chemotherapy. It tests if giving a common drug (Azacitidine) for 5 days instead of 7 days might cause fewer side effects while still working well.